2016 Half-Year Results

Corporate Half-Year 2016 - Best First Half in History ■ 20% CORE EBIT growth and 6% sales growth Lonza Both Pharma&Biotech and Specialty Ingredients segments improved their profitability Pharma&Biotech's outstanding operational performance across all assets bolstered the strong half-year results 2016 guidance raised: Double-digit CORE EBIT growth expected for 2016 Stable cash flow generation and de-leveraging ongoing ■ Net debt was further reduced by CHF 337 million 2016 Half-Year Results - 20 July 2016 4 Jul-16

View entire presentation